LPA Receptor

SAR-100842 is a lysophaphatidic acid 1 (LPA1/Edg-2) receptor inhibitor.

CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β), showing significant inhibition of tumor cell growth. It exhibits IC50 values in the range of 0.1-0.8 μM across various leukemia cell lines and effectively induces caspase activation in DHL-4 and Ramos cells. In combination with Rituximab, CT 32228 promotes apoptosis and demonstrates a 50% growth delay in xenograft models. This reagent is suitable for research applications targeting acute leukemia.

BrP-LPA is a potent lysophosphatidic acid (LPA) antagonist and autotoxin (ATX) inhibitor. It exhibits broad-spectrum antagonism against LPA receptors LPA1-4, resulting in decreased blood vessel density and reduced anxiety-like behaviors. Additionally, BrP-LPA demonstrates significant anticancer activity, effectively inhibiting cell proliferation in breast, colon, and lung cancer models. This compound is valuable for research focused on cancer biology and vasculature modulation.

L-NASPA ammonium is an effective LPA inhibitor that targets lysophosphatidic acid signaling pathways. It is utilized in research focused on platelet activation and related cellular processes. By inhibiting LPA, this compound aids in elucidating the mechanisms underlying platelet function and potential therapeutic interventions in related disorders.

L-NASPA is a potent lysophosphatidic acid (LPA) inhibitor that plays a significant role in research related to platelet activation. By blocking LPA signaling pathways, L-NASPA enables the investigation of its effects on cellular processes involved in thrombosis and inflammation. This compound is valuable for studies aimed at understanding the physiological and pathological roles of LPA in various biological contexts.